Literature DB >> 20036440

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

David P Carbone1, J Stuart Salmon, Dean Billheimer, Heidi Chen, Alan Sandler, Heinrich Roder, Joanna Roder, Maxim Tsypin, Roy S Herbst, Anne S Tsao, Hai T Tran, Thao P Dang.   

Abstract

We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat) in a blinded manner to pretreatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20036440      PMCID： PMC2891357          DOI： 10.1016/j.lungcan.2009.11.019

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  10 in total

1.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

3.  Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

Authors:  Roy S Herbst; David H Johnson; Eric Mininberg; David P Carbone; Ted Henderson; Edward S Kim; George Blumenschein; Jack J Lee; Diane D Liu; Mylene T Truong; Waun K Hong; Hai Tran; Anne Tsao; Dong Xie; David A Ramies; Robert Mass; Somasekar Seshagiri; David A Eberhard; Sean K Kelley; Alan Sandler
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

4.  Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.

Authors:  Stuart Salmon; Heidi Chen; Shuo Chen; Roy Herbst; Anne Tsao; Hai Tran; Alan Sandler; Dean Billheimer; Yu Shyr; Ju-Whei Lee; Pierre Massion; Julie Brahmer; Joan Schiller; David Carbone; Thao P Dang
Journal:  J Thorac Oncol       Date:  2009-06       Impact factor: 15.609

5.  Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

Authors:  Fumiko Taguchi; Benjamin Solomon; Vanesa Gregorc; Heinrich Roder; Robert Gray; Kazuo Kasahara; Makoto Nishio; Julie Brahmer; Anna Spreafico; Vienna Ludovini; Pierre P Massion; Rafal Dziadziuszko; Joan Schiller; Julia Grigorieva; Maxim Tsypin; Stephen W Hunsucker; Richard Caprioli; Mark W Duncan; Fred R Hirsch; Paul A Bunn; David P Carbone
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

Review 6.  Bevacizumab in the treatment of non-small-cell lung cancer.

Authors:  T E Stinchcombe; M A Socinski
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

7.  Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Authors:  Roy S Herbst; Vincent J O'Neill; Louis Fehrenbacher; Chandra P Belani; Philip D Bonomi; Lowell Hart; Ostap Melnyk; David Ramies; Ming Lin; Alan Sandler
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

8.  Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.

Authors:  Jean-Yves Douillard; Silvy Laporte; Frank Fossella; Vassilis Georgoulias; Jean-Louis Pujol; Kaoru Kubota; Alain Monnier; Shinzoh Kudoh; Jaime Ernesto Rubio; Michel Cucherat
Journal:  J Thorac Oncol       Date:  2007-10       Impact factor: 15.609

9.  Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.

Authors:  Afshin Dowlati; Robert Gray; Alan B Sandler; Joan H Schiller; David H Johnson
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 10.  Angiogenesis and lung cancer: prognostic and therapeutic implications.

Authors:  Roy S Herbst; Amir Onn; Alan Sandler
Journal:  J Clin Oncol       Date:  2005-05-10       Impact factor: 44.544
  10 in total
  26 in total

1.  Imaging: Mass spectrometry in HNSCC--a peek at response prediction?

Authors:  Mei-Kim Ang; D Neil Hayes
Journal:  Nat Rev Clin Oncol       Date:  2010-04       Impact factor: 66.675

Review 2.  Molecular testing in lung cancer: the time is now.

Authors:  Haiying Cheng; Xunhai Xu; Daniel B Costa; Charles A Powell; Balazs Halmos
Journal:  Curr Oncol Rep       Date:  2010-09       Impact factor: 5.075

3.  The value of proteomics in lung cancer.

Authors:  Anthonie J van der Wekken; Thijo J N Hiltermann; Harry J M Groen
Journal:  Ann Transl Med       Date:  2015-03

4.  Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Authors:  Shadi Ferdosi; Douglas S Rehder; Paul Maranian; Erik P Castle; Thai H Ho; Harvey I Pass; Daniel W Cramer; Karen S Anderson; Lei Fu; David E C Cole; Tao Le; Xifeng Wu; Chad R Borges
Journal:  J Proteome Res       Date:  2017-11-21       Impact factor: 4.466

5.  Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.

Authors:  David P Carbone; Keyue Ding; Heinrich Roder; Julia Grigorieva; Joanna Roder; Ming-Sound Tsao; Lesley Seymour; Frances A Shepherd
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

Review 6.  Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.

Authors:  Mariette Labots; Lisette M Schütte; Johannes C van der Mijn; Thang V Pham; Connie R Jiménez; Henk M W Verheul
Journal:  Oncologist       Date:  2014-09-03

7.  SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.

Authors:  Primo N Lara; James Moon; Paul J Hesketh; Mary W Redman; Stephen K Williamson; Wallace L Akerley; Fred R Hirsch; Philip C Mack; David R Gandara
Journal:  J Thorac Oncol       Date:  2015-12-25       Impact factor: 15.609

8.  Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.

Authors:  Mani Keshtgarpour; Wei Seong Tan; Jack Zwanziger; Saria Awadalla; Fredrick G Langi; Arkadiusz Z Dudek
Journal:  Anticancer Res       Date:  2016-04       Impact factor: 2.480

Review 9.  Proteomic biomarkers in lung cancer.

Authors:  M D Pastor; A Nogal; S Molina-Pinelo; A Carnero; L Paz-Ares
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

10.  Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Authors:  Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.